PRP Regulatory Progress – Canada

Summary by AI BETAClose X

Genus PLC has announced a significant regulatory milestone as Canada has approved the use of its PRRS Resistant Pig (PRP) gene edit, a crucial step towards commercialisation in North America. This development follows extensive collaboration with Canadian regulatory bodies and addresses the substantial economic impact of PRRS, which a 2024 study estimated costs the U.S. $1.2 billion annually and increases antibiotic usage by over 200%. Genus is actively pursuing further approvals in key export markets like Mexico and Japan, as well as engaging with regulators in China.

Disclaimer*

Companies

Genus (GNS)
UK 100

Latest directors dealings